表皮生长因子受体酪氨酸激酶抑制剂作为完全切除的非小细胞肺癌的辅助治疗 - Suppr

Suppr

超能文献

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer.

作者信息

Novello Silvia

机构信息

University of Turin, Torino, Italy

出版信息

J Clin Oncol. 2015 Dec 1;33(34):3985-6. doi: 10.1200/JCO.2015.63.7587. Epub 2015 Oct 5.

DOI:10.1200/JCO.2015.63.7587

PMID:26438112

Abstract

摘要

相似文献

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer.表皮生长因子受体酪氨酸激酶抑制剂作为完全切除的非小细胞肺癌的辅助治疗

J Clin Oncol. 2015 Dec 1;33(34):3985-6. doi: 10.1200/JCO.2015.63.7587. Epub 2015 Oct 5.

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.厄洛替尼辅助治疗与安慰剂对照用于 IB 期-IIIA 期非小细胞肺癌患者（RADIANT）：一项随机、双盲、III 期临床试验。

J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

Adjuvant TKIs in NSCLC: what can we learn from RADIANT?非小细胞肺癌中的辅助性酪氨酸激酶抑制剂：我们能从RADIANT研究中学到什么？

Nat Rev Clin Oncol. 2015 Dec;12(12):689-90. doi: 10.1038/nrclinonc.2015.202. Epub 2015 Nov 10.

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.JO22903研究的最终总生存期，这是一项针对日本EGFR突变阳性非小细胞肺癌患者的一线厄洛替尼的II期开放标签研究。

Int J Clin Oncol. 2017 Feb;22(1):70-78. doi: 10.1007/s10147-016-1039-0. Epub 2016 Sep 22.

Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion.厄洛替尼作为一名患有脉络膜转移且伴有表皮生长因子受体第19外显子缺失的非小细胞肺癌患者的一线治疗药物。

J BUON. 2016 May-Jun;21(3):754-5.

MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut.MuTAR研究，一项关于厄洛替尼（E）治疗表皮生长因子受体（EGFR）酪氨酸激酶（TKI）结构域存在激活突变（MUT+）的局部晚期或转移性非小细胞肺癌（mNSCLC）患者（pts）的II期开放标签研究，评估了厄洛替尼一线治疗葡萄牙mNSCLC EGFR突变患者的疗效。

Rev Port Pneumol (2006). 2016 Sep-Oct;22(5):287-8. doi: 10.1016/j.rppnen.2016.03.009. Epub 2016 May 6.

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.靶向治疗时代的营养状况：营养不良是表皮生长因子受体激活突变的非小细胞肺癌的一个预后因素。

Korean J Intern Med. 2016 Nov;31(6):1140-1149. doi: 10.3904/kjim.2015.062. Epub 2016 Mar 28.

Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.在不携带更常见表皮生长因子受体突变的非小细胞肺癌肿瘤中，厄洛替尼反应的生物标志物。

Int J Clin Exp Pathol. 2015 Mar 1;8(3):2888-98. eCollection 2015.

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.厄洛替尼对吉非替尼治疗失败后的非小细胞肺癌患者的挽救治疗临床疗效。

Korean J Intern Med. 2015 Nov;30(6):891-8. doi: 10.3904/kjim.2015.30.6.891. Epub 2015 Oct 30.

引用本文的文献

Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis.表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌的不良反应谱：一项更新的荟萃分析。

Target Oncol. 2024 Jul;19(4):547-564. doi: 10.1007/s11523-024-01073-w. Epub 2024 Jun 1.

A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations.一种用于预测具有 EGFR 激活突变的非小细胞肺癌治疗反应的荧光探针。

Nat Commun. 2022 Nov 14;13(1):6944. doi: 10.1038/s41467-022-34627-5.

Development and Validation of Machine Learning Models to Predict Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer: A Multi-Center Retrospective Radiomics Study.开发和验证机器学习模型预测非小细胞肺癌表皮生长因子受体突变：一项多中心回顾性放射组学研究。

Cancer Control. 2022 Jan-Dec;29:10732748221092926. doi: 10.1177/10732748221092926.

Application of CT radiomics features to predict the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung adenocarcinoma.CT影像组学特征在预测晚期肺腺癌EGFR突变状态及对酪氨酸激酶抑制剂治疗敏感性中的应用

Transl Cancer Res. 2020 Nov;9(11):6683-6690. doi: 10.21037/tcr-20-1216.

The application of radiomics in predicting gene mutations in cancer.放射组学在预测癌症基因突变中的应用。

Eur Radiol. 2022 Jun;32(6):4014-4024. doi: 10.1007/s00330-021-08520-6. Epub 2022 Jan 20.

The Potential of Radiomics Nomogram in Non-invasively Prediction of Epidermal Growth Factor Receptor Mutation Status and Subtypes in Lung Adenocarcinoma.放射组学列线图在非侵入性预测肺腺癌表皮生长因子受体突变状态及亚型中的潜力

Front Oncol. 2020 Jan 9;9:1485. doi: 10.3389/fonc.2019.01485. eCollection 2019.

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC.Notch3 依赖性 β-连环蛋白信号通路介导 EGFR 突变型 NSCLC 对 EGFR-TKI 药物的耐药性。

Nat Commun. 2018 Aug 10;9(1):3198. doi: 10.1038/s41467-018-05626-2.

Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma.丝氨酸207磷酸化的赖氨酰-tRNA合成酶可预测非小细胞肺癌的无病生存期。

Oncotarget. 2017 May 22;8(39):65186-65198. doi: 10.18632/oncotarget.18053. eCollection 2017 Sep 12.

Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?切除的非小细胞肺癌的辅助治疗：我们能取得进展吗？

Curr Treat Options Oncol. 2016 Oct;17(10):54. doi: 10.1007/s11864-016-0429-x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验